Immuneering (IMRX) announced the appointment of Thomas Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering’s Strategic Advances and Positive Outlook Boost Buy Rating and Price Target
- Immuneering to announce updated data from Phase 2a trial of Atebimetinib + mGnP
- Immuneering files to sell 9.18M shares of Class A common stock for holders
- Immuneering’s Strategic Partnerships and Promising Clinical Developments Justify Buy Rating
- Immuneering announces clinical supply agreement with Eli Lilly